source
- Amgen initiates three late-stage trials of obesity shot MariTide, including a switch-patient studyAmgen announced the start of three new Phase 3 trials for its long-acting obesity injection, MariTide. One of the studies will enroll participants who are transitioning away from the GLP-1 therapi…
- Axsome receives FDA nod for Alzheimer’s agitation treatmentAxsome announced that the U.S. Food and Drug Administration granted it a nod for a therapy aimed at agitation associated with Alzheimer’s disease, according to the STAT+ report. The decision marks…